Injectables boosts Hikma revenues

Hikma Pharmaceuticals, which is listed on Nasdaq Dubai, said its revenues in the first half of 2014 increased 16 per cent to $738 million (Dh2.7 billion), driven by the strong performance of the injectables business.

Hikma continued to build its global product portfolio with the launch of 49 new products while 140 product approvals were received in the first half of 2014.

“In the Mena region, our focus on new, higher value products is delivering strong results in key markets,” said Said Darwazah, Chief Executive Officer of Hikma. “Our Injectables business delivered an excellent performance, as we captured a number of attractive market opportunities,” he said.

“I am delighted we have acquired the Bedford assets, which will add products, R&D capabilities and capacity to support future growth for the global Injectables business. Our Generics business is performing extremely well and we are working hard to strengthen the product portfolio and pipeline,” added Darwazah.

(Home page image courtesy Shutterstock)

Follow Emirates 24|7 on Google News.